

Damien Kee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4638585/publications.pdf>

Version: 2024-02-01

18
papers

2,922
citations

759233

12
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

4495
citing authors

#	ARTICLE	IF	CITATIONS
1	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. <i>Acta Neuropathologica</i> , 2022, 143, 109-113.	7.7	11
2	Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. <i>Oncoimmunology</i> , 2021, 10, 1908771.	4.6	21
3	Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2021, 39, 592-593.	16.8	41
4	Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.	0.9	42
5	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995.		18
6	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
7	Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 323-327.	2.8	2
8	Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2020, 6, 1405.	7.1	157
9	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. <i>Modern Pathology</i> , 2020, 33, 1811-1821.	5.5	19
10	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 4454-4459.	7.0	110
11	CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 136-146.	2.1	1
12	Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy. <i>Melanoma Research</i> , 2020, 30, 608-612.	1.2	5
13	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
14	Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. <i>Medical Journal of Australia</i> , 2014, 201, 49-53.	1.7	52
15	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 954-965.	10.7	225
16	Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 255-270.	3.2	42
17	<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. <i>New England Journal of Medicine</i> , 2012, 366, 207-215.	27.0	978
18	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. <i>Cancer Cell</i> , 2010, 18, 683-695.	16.8	1,139